BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26022202)

  • 1. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
    Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
    Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
    Sasajima T; Ono T; Shimada N; Doi Y; Oka S; Kanagawa M; Baden A; Mizoi K
    Nucl Med Biol; 2013 Aug; 40(6):808-15. PubMed ID: 23701701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IIa clinical study of [
    Kondo A; Ishii H; Aoki S; Suzuki M; Nagasawa H; Kubota K; Minamimoto R; Arakawa A; Tominaga M; Arai H
    Ann Nucl Med; 2016 Nov; 30(9):608-618. PubMed ID: 27418267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of transport mechanisms of trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid and L-[methyl-¹¹C]methionine in human glioma cell lines.
    Ono M; Oka S; Okudaira H; Schuster DM; Goodman MM; Kawai K; Shirakami Y
    Brain Res; 2013 Oct; 1535():24-37. PubMed ID: 23994214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas.
    Karlberg A; Berntsen EM; Johansen H; Skjulsvik AJ; Reinertsen I; Dai HY; Xiao Y; Rivaz H; Borghammer P; Solheim O; Eikenes L
    Clin Nucl Med; 2019 Jul; 44(7):550-559. PubMed ID: 31107743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats.
    Kanagawa M; Doi Y; Oka S; Kobayashi R; Nakata N; Toyama M; Shirakami Y
    Nucl Med Biol; 2014 Aug; 41(7):545-51. PubMed ID: 24816330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of anti-3-[
    Karlberg A; Pedersen LK; Vindstad BE; Skjulsvik AJ; Johansen H; Solheim O; Skogen K; Kvistad KA; Bogsrud TV; Myrmel KS; Giskeødegård GF; Ingebrigtsen T; Berntsen EM; Eikenes L
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):496-509. PubMed ID: 37776502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
    Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
    J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
    Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
    Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Albano D; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Ann Nucl Med; 2020 Feb; 34(2):81-86. PubMed ID: 31773466
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.
    Oka S; Hattori R; Kurosaki F; Toyama M; Williams LA; Yu W; Votaw JR; Yoshida Y; Goodman MM; Ito O
    J Nucl Med; 2007 Jan; 48(1):46-55. PubMed ID: 17204698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors.
    Shoup TM; Olson J; Hoffman JM; Votaw J; Eshima D; Eshima L; Camp VM; Stabin M; Votaw D; Goodman MM
    J Nucl Med; 1999 Feb; 40(2):331-8. PubMed ID: 10025843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose.
    Oka S; Okudaira H; Ono M; Schuster DM; Goodman MM; Kawai K; Shirakami Y
    Mol Imaging Biol; 2014 Jun; 16(3):322-9. PubMed ID: 24136390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.
    Hutterer M; Nowosielski M; Putzer D; Jansen NL; Seiz M; Schocke M; McCoy M; Göbel G; la Fougère C; Virgolini IJ; Trinka E; Jacobs AH; Stockhammer G
    Neuro Oncol; 2013 Mar; 15(3):341-51. PubMed ID: 23335162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
    Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal
    Karlberg A; Berntsen EM; Johansen H; Myrthue M; Skjulsvik AJ; Reinertsen I; Esmaeili M; Dai HY; Xiao Y; Rivaz H; Borghammer P; Solheim O; Eikenes L
    World Neurosurg; 2017 Dec; 108():989.e1-989.e8. PubMed ID: 28844925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of blood-brain barrier permeability on O-(2-
    Stegmayr C; Bandelow U; Oliveira D; Lohmann P; Willuweit A; Filss C; Galldiks N; Lübke JH; Shah NJ; Ermert J; Langen KJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):408-416. PubMed ID: 27613541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.